Human papillomaviral load changes in low-grade squamous intraepithelial lesions of the uterine cervix by Ho, C-M et al.
Human papillomaviral load changes in low-grade squamous
intraepithelial lesions of the uterine cervix
C-M Ho
1,2,3, W-F Cheng
4, T-Y Chu
5, C-A Chen
4, M-H Chuang
6, S-F Chang*,3 and C-Y Hsieh
4
1Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan, ROC;
2School of Medicine, Fu Jen
Catholic University, Hsinchuang, Taipei, Hsien, Taiwan, ROC;
3Graduate Institute of Cell and Molecular Biology, Taipei Medical University, 250 Wu-Hsing
Street, Taipei, Taiwan 110, ROC;
4Department of Obstetrics and Gynecology, National Taiwan University Hospital, National Taiwan University, Taipei,
Taiwan, ROC;
5Department of Obstetrics and Gynecology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, ROC;
6Division of Biostatistics and
Bioinformatics, National Health Research Institutes, Miaoli, Taiwan, ROC
To better predict risk of progression of low-grade squamous intraepithelial lesions (LSILs) of the uterine cervix in women with human
papillomavirus (HPV) infections, 294 baseline cervical specimens from women with LSILs were evaluated. Specimens were tested for
HPV DNA using hybrid capture 2 (HC2) and PCR-reverse line blotting. 65 LSILs with HPV DNA types 16, 18, 52, or 58 were
examined for physical status, E2/E6 ratio and viral load at two time points, along with patient age. Women with LSILs whose viral
loads increased between baseline and 6 month follow-up had a 45% risk of developing HSIL (OR¼7.6, 95% CI¼1.9–29.4,
Po0.01), as evaluated by real-time PCR and a 44% risk (OR¼6.1, 95% CI¼1.6–22.7, Po0.01), as evaluated by HC2. The two viral
load measures correlated well (Person’s coefficient, r¼0.687, Po0.001). Such evaluations of viral load changes (increased or not
increased) through repeat HPV DNA testing could predict progression of disease in LSIL cases of HPV types 16, 18, 52, and 58,
which correlates to clinical implications.
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Human papillomavirus (HPV) plays an important role in the
carcinogenesis of cervical cancer (Bosch et al, 1995; Walboomers
et al, 1999). The most common oncogenic HPV type in preinvasive
and cervical cancer is HPV 16, detectable in 21% of women
with low-grade squamous intraepithelial lesions (LSILs) (Castle
et al, 2005), in more than 50% of women with cervical
intraepithelial neoplasia grade 3 (CIN 3), and women with cervical
cancer in America and Europe (Bosch et al, 1995; Herrero et al,
2000; Munoz et al, 2003). HPV 18 causes 10–15% of CIN 3
and cervical cancers (Bosch et al, 1995). In addition, HPV 18
also causes more than 35% of cervical adenocarcinomas, which
are difficult to detect by current screening methods (Bosch et al,
1995). Additionally, HPV 52 and 58 are as prevalent as HPV 16 and
18 in patients with preinvasive and cervical cancer in Taiwan and
Asian countries (Liaw et al, 1995; Huang et al, 1997; Ho et al, 2005,
2006).
Approximately 50% of atypical squamous cells of undetermined
significance (ASCUS) and 80% of LSILs are infected by oncogenic
types of HPV (ALTS group, 2000; Solomon et al, 2001). HPV DNA
testing for patients with ASCUS provides useful information and
allows referral of patients for immediate colposcopy to detect high-
grade squamous intraepithelial lesions (HSILs) and cancer
(Solomon et al, 2001). In contrast, oncogenic HPV DNA testing
is not informative for triage of patients with LSILs because a high
percentage of LSIL patients are HPV positive (ALTS group, 2000).
A repeat Pap smear in 3–6 months or direct biopsy under
colposcopy is generally used in clinical practice. Development of
alternative triage strategies for women with LSILs would be
valuable in distinguishing women with LSILs that have high
probabilities of progression to HSILs from women with LSILs that
have spontaneously regressed.
As a result of the lack of sufficiently large prospective
longitudinal follow-up studies and the different geographic
distributions of HPV types, it has not been established how the
risk of HSILs differs during transition by physical status of HPV
16, 18, 52, and 58 DNA (integrated versus episomal DNA) during
longitudinal follow-up, viral loads (high vs low) and viral load
change (increased vs not increased) between baseline and follow-
up among women with LSILs. To examine this issue, we evaluated
the 2-year cumulative risk for HSIL attributable to HPV 16, 18, 52,
and 58, the most common oncogenic types in pre-invasive cervical
lesions including LSILs and HSILs in Asia, and questioned whether
the integration of HPV oncogenes into a host genome contributed
to the risk of LSILs progressing to HSILs. In addition, we
determined if E6 viral load and its change contributed to the risk of
LSILs progressing to HSILs during the 6-month interval between
baseline diagnosis of LSIL by Pap smear and the 6-month follow-
up visit by repeat Pap smear.
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sSUBJECTS AND METHODS
The Taiwan Cooperative Oncology Group (TCOG), conducted a
multicenter study – T1899, entitled, ‘Human Papillomavirus DNA
in Squamous Intraepithelial Lesions and Longitudinal Follow-up of
Its Clinical Significance in Low-grade Squamous Intraepithelial
Lesions of Uterine Cervix’, under the supervision of the National
Health Research Institute of Taiwan. A total of 1246 women with
abnormal Pap smears, including those diagnosed with ASCUS or
AGUS (n¼431), LSIL (n¼437), and HSIL (n¼373), from August
1999 to March 2004 were enrolled. The details of the study design
and population have been published (Sun et al, 2005; Chen et al,
2006). Of the 1246 participants, 936 underwent cervical biopsies
for histological examinations.
Women with LSIL (n¼437) had Pap smears, HPV testing, and
colposcopic examinations every 3 months during the follow-up
period. Participants were excluded from the study if they had no
follow-up data (n¼60), baseline cancer on pathological examina-
tion (n¼1), fewer than four follow-up visits (n¼82), or no
baseline HPV data (n¼2). Women with histologically confirmed
HSIL were defined as having disease progression were treated and
exited from the study. Women with LSIL with two consecutive
normal Pap smears and showed HPV clearance during the follow-
up period were defined as in remission and also exited. Women
with LSIL not in remission or progression were defined as having
persistent disease. HPV persistence was defined as HPV positivity
for a given type tested on two consecutive occasions vs clearance.
A total of 294 women with LSIL, having at least four follow-up
visits every 3 months, were tested for HPV DNA using both HC2
and PCR-reverse line blotting and were included in our long-
itudinal follow-up study (unpublished data). Among the 294
patients with LSIL, 187 specimens from 65 women with HPV 16
(n¼14), 18 (n¼8), 52 (n¼30), and 58 (n¼13) were collected at
baseline and followed-up every 6 months until follow-up showed
disease progression. Patients with LSIL from HPV types other than
HPV 16, 18, 52, or 58 were excluded from our study due to diffuse
distribution and relatively small sample sizes in each type. The
specimens were further tested for viral load, E2/E6 ratio and viral
load change using real-time PCR. Of the 187 specimens, 12 (6%)
were mixed infections. Four samples lacking of follow-up HPV
DNA were excluded from final analysis. In addition, 212 HSIL
positive patients with HPV 16 (n¼92), 18 (n¼5), 52 (n¼57), or
58 (n¼58) infections were also obtained and tested for viral load,
E2/E6 ratio, and physical status of HPV DNA using real-time PCR
to compare with data from LSIL specimens. We also tested the
specimens for viral load and viral load change by hybrid capture
two and compared these results to those obtained by real-time PCR
to predict disease progression.
HPV DNA testing-HC2 and PCR methods
HC2 (Digene Corporation, Silver Spring, MD, USA) was used to
examine for HPV DNA in each specimen, including a mixture of
probes for cervical cancer-associated HPV types: 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, and 68. The US Food and Drug
Administration approved threshold of 1pg of HPV DNAml
 1 of
test solution was the positive control. The viral loads were
expressed as copies of HPV genomes/100ng. For the PCR method,
MY09-MY-11-HMB01 L1 consensus primers were used in the
amplification system, followed by a single hybridisation with a
reverse line blot detection method (the prototype of Roche linear
array HPV test, Roche Molecular Systems Inc., Pleasanton, CA,
USA). The HPV genotyping strips contained 29 probe lines plus
one reference line, detecting 27 individual HPV genotypes and two
concentrations of the b-globin control probe. Two bovine serum
albumin (BSA)-conjugated probes per HPV probe per HPV type,
corresponding to each of two hypervariable regions within the
MY09/MY11 amplicon, were deposited in a single line for each of
the following HPV types: 16, 18, 26, 31, 33, 35, 39, 42, 45, 51–59,
66, 68, MM4, MM7, MM8, and MM9.
Real-time PCR
DNA amplifications were carried out in a 96-well reaction plate
format in an ABI Prism 5700 Sequence Detection System.
Amplification and quantification of the E2 and E6 genes were
performed simultaneously in separate reaction tubes. Both the
HPV E2 and E6 PCR reactions were performed in triplicate.
Multiple negative water blanks were included in every analysis.
The reactions of real-time PCR are described elsewhere (Ho et al,
2006). The specificity was verified by a dissociation curve. Two
standard curves were obtained by amplification of a serial dilution
of cloned HPV-16 (from base 28 to base 3890) or HPV-18 (from
base 45 to base 3993) DNA fragments or HPV-52 (from base 95 to
base 3895) or HPV-58 (from base 45 to base 3994) DNA in pGEM
T-Easy vector containing equivalent amounts of E2 and E6 genes
from 10 to 10000000copiesml
 1. The number of threshold cycles
obtained from E2 PCR and from E6 PCR was equivalent in each
run. Linear plots of the log of copy number vs the number of the
threshold cycle were consistently obtained for both genes, and the
correlation coefficient was between 0.995 and 1.00 in each run.
The technique was developed on the assumption that: (1)
preferential disruption of E2 causes the absence of E2 gene
sequences in the PCR product following integration, (2) copy
numbers of both genes should be equal when viral DNA presents
in episomal forms, and (3) E2 gene copy numbers are smaller than
that for E6 in concomitant forms.
Concentrations of HPV DNA were expressed as copies of the
HPV genome in 100ng of cellular DNA. Ratios of E2–E6 of less
than 1 indicated the presence of both integrated and episomal
forms. The integrated E6 was calculated by subtracting the copy
numbers of E2 (episomal). The ratio of E2 to integrated E6
represented the amount of the episomal form in relation to the
integrated form.
Statistical analyses
The 2-year cumulative risks stratified by the change of viral load at
the first two time points (viral load increased or not increased) for
histologically confirmed HSIL attributable to HPV 16, 18, 52, or 58
were analysed via the Kaplan-Meier method. Logistic regression
analysis was used to calculate the odds ratios (OR) and their 95%
confidence intervals (CIs) for HSIL associated with change of HPV
load (increased vs not increased), high viral load (410
5 vs p10
5),
age (X 30 vs o30 years) and repeat Pap smear (abnormal vs
normal). The correlation between HPV loads determined by real-
time PCR and HC2 was estimated using Pearson’s correlation. The
differences in HPV integration status between LSIL and HISL
groups were analysed using Fisher’s exact test. All statistical
analyses were performed using SAS 9.13.
RESULTS
Among the 294 women with LSIL having at least four follow-up
visits in 3 months, 76.9% were HPV DNA positive by PCR. The
frequencies of the major, baseline HPV genotypes were: HPV 16
(4.8%), 18 (2.4%), 52 (10.9%), 58 (4.1%), 53 (8.5%), and 51 (6.8%).
The prevalence of HPV 16, 18, 52, and 58 in HSIL were as follows:
31.7% (92/290) – type 16, followed by 20.0% (58/290) – type 58,
19.7% (57/290) – type 52, and 1.7% (5/290) – type 18.
Median E6 viral loads
For the 61 eligible women with LSILs, the clinical characteristics
and median viral loads are shown in Table 1. The median viral
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sloads of HPV types 16 and 52 among women with LSILs and HSILs
differed significantly (P¼0.049 for HPV 16 E6, P¼0.032 for HPV
52 E6). The median viral loads of HPV types 18 and 58 among
women with LSILs and HSILs did not differ significantly (P¼0.499
for type 18, P¼0.184 for type 58). The median viral load ranged
from 1.3 10
4 to 3.7 10
4 copies per 100ng of DNA. Therefore,
high viral loads were defined as those greater than 10
5 copies per
100ng of DNA. The HPV 16, 18, 52, or 58 viral loads tested by real-
time PCR varied from 2.4 10
2–7.6 10
6 copies per 100ng of
DNA, which is equivalent to 15151 cells. Whereas, the HPV 16, 18,
52, or 58 loads tested by HC2 varied from 5.1 10
3–1.1 10
8
copies per 100ng of DNA, which is equivalent to about 15000 cells.
Women who had high viral loads (410
5 copies) vs low viral loads
(p10
5 copies) at baseline had marginally significant increased risk
of disease progression (P¼0.07).
Two-year cumulative risk with dynamic change of HPV
Overall, 61 women after cytological examination with LSILs
attributable to HPV 16, 18, 52, or 58 had a 2-year cumulative
risk of developing HSILs of 21.5%, 29.3% (4/14) with HPV 16
(OR¼1.5, 95% CI¼0.4–5.8, P¼0.34), 12.5% (1/8) with HPV 18
(OR¼0.6, 95% CI¼0.1–5.3, P¼0.23), 26.9% (7/26) with HPV 52
(OR¼0.7, 95% CI¼0.2–2.6, P¼0.34), and 7.7% (1/13) with HPV
58 (OR¼0.3, 95% CI¼0.0–2.1, P¼1.61) (Figure 1).
Based on viral load changes detected using real-time PCR,
women with LSILs who had viral loads increases for HPV 16, 18,
52, or 58 between baseline and a 6 month follow-up had a 2-year
risk of developing HSIL of 45%, seven-fold greater than those
without increases in viral loads (OR¼7.6, 95% CI¼1.9–24.3,
Po0.01) (Figure 2). Overall, women with LSILs and persistent
HPV infections had a 2-year cumulative risk of developing HSILs
of 25%, compared –11.5% for those with transient infections
(OR¼2.5, 95% CI¼0.5–12.7, P¼0.27) (Figure 3).
Women with LSILs due to HPV 16, 18, 52, or 58, who had
increases in viral loads between baseline and 6 month follow-up
had risk of persistent abnormal Pap smears 45-fold greater than
those without increased viral loads (OR¼45.6, 95% CI¼6.4–
326.0, Po0.001).
Using logistic regression for modelling changes in viral load
data, repeat abnormal Pap smears, and patient age at enrollment,
women with LSILs who had viral loads increase between baseline
and 6 month follow-up for HPV 16, 18, 52, or 58 had increased risk
for HSILs, as tested by real-time PCR (OR¼8.3, 95% CI¼2.0–34,
Po0.01) or HC2 (OR¼5.6, 95% CI¼1.5–21.4, Po0.01). In
addition, women with LSILs, repeat abnormal Pap smears
(OR¼2.1, 95% CI¼0.5–8.3, P40.05), and aged younger than 30
years (OR¼1.8, 95% CI¼0.3–11.7, P40.05) did not show an
increase in risk of developing HSILs (Table 2).
Comparison of HPV viral load by HC2 and real-time PCR
Real-time PCR and HC2 correlated well for determining viral load
change (increased or not increased) at baseline and 6-month
follow-up to predict disease progression. Based on viral load
change tested by HC2, women with LSILs due to HPV 16, 18, 52, or
58 who had viral load increase between baseline and 6 month
follow-up had risk of developing HSILs of 44%, six-fold greater
Table 1 Clinical characteristics and median E6 load for LSIL of 61 eligible women with LSILs due to HPV 16, 18, 52, or 58 with at least four follow-up visits
HPV 16 HPV 18 HPV 52 HPV 58
Percentage of each type 23.0% (14/61) 13.1% (8/61) 42.6% (26/61) 21.3% (13/61)
Median age (range) 35 (range: 24–58) 31 (range: 23–51) 41 (range: 24–65) 38 (range: 20–52)
Median E6 load for LSIL 13437 26599 35620 37366
Range of viral load for LSIL 0–735527 0–5029143 0–3843486 0–2754113
Median E6 load for HSIL 31916 21067 156906 110107
Range of viral load for HSIL 0–34386322 0–41748 0–13596437 0–14243132
P-value (median E6 load between LSIL and HSIL) 0.049 0.499 0.032 0.184
HSILs¼high-grade squamous intraepithelial lesions.
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Figure 1 Kaplan–Meier estimates of cumulative incidence of high-grade squamous intraepithelial lesions (HSILs) among the 61 women with low-grade
squamous intraepithelial lesions (LSILs), according to HPV types 16, 18, 52, and/or 58.
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sthan those without increased viral loads (OR¼6.1, 95% CI¼1.6–
22.7). This result is consistent with real-time PCR of 45%, seven-
fold greater than those without increased viral loads by real-time
PCR. The logarithm of HPV 16, 18, 52, or 58 viral loads estimated
by real-time PCR were plotted as functions of the logarithm of
HPV viral loads estimated by HC2. The two measurements for viral
load correlated well (Pearson’s correlation coefficient r¼0.69,
Po0.001).
Physical status of HPV 16, 18, 52, and 58 DNA in women
with LSILs and longitudinal follow-up
The prevalence of both integrated and episomal (mixed type)
infections for women with LSILs at baseline for HPV 16, 18, 52,
and 58 were as follows: 7.1% (1/14) – type 16, 12.5% (1/8) – type
18, 7.7% (2/26) – type 52, and 0% (0/13) – type 58. No pure single
type of viral integration was found in women with LSILs due to
HPV 16, 18, 52, and 58 at baseline or during follow-up. Integrated
and episomal HPV 16, 18, 52, or 58 DNA was detected in only 1 of
13 (7.7%) specimens in progression among women during
transition from LSILs to HSILs. The prevalence of integration of
HPV 16, 18, 52, or 58 DNA between women with LSILs and HSILs
increased significantly (Po0.001). A significant difference or trend
in the physical status of HPV 52, 18, or 58 DNA was found between
patients with LSILs and HSILs (Po0.001 for type 52, P¼0.067 for
type 18, and P¼0.065 for HPV 58). However, no significant
difference in the physical status of HPV 16 DNA was found
between patients with LSILs and HSILs (P¼0.46). When the
comparison was confined to tissue proved HSIL cases, the
prevalence of integration of HPV 16, 18, 52, or 58 DNA between
LSIL and HSIL cases was still significantly increased (Po0.001). A
significant difference or trend in the physical status of HPV 52 or
0.46
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Figure 2 Kaplan–Meier estimates of cumulative incidence of high-grade squamous intraepithelial lesions (HSILs) among the 61 women with low-grade
squamous intraepithelial lesions (LSILs), according to viral load change of HPV for HPV 16, 18, 52, and 58 (load increased vs not increased).
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Figure 3 Kaplan–Meier estimates of cumulative incidence of high-grade squamous intraepithelial lesions (HSILs) among the 61 women with low-grade
squamous intraepithelial lesions (LSILs), according to transient vs persistent infection of HPV with HPV 16, 18, 52, and/or 58.
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s58 DNA was found between patients with LSILs and HSILs
(Po0.001 for type 52, and P¼0.082 for HPV 58). However, the
physical status of HPV 16 and 18 DNA was not significantly
different between patients with LSILs and HSILs (P¼0.3 for type
16 and P¼0.22 for type 18).
DISCUSSION
In our study population of women with LSILs, viral loads for HPV
16, 18, 52, and 58 increased during the 6 months of follow-up after
baseline values were obtained. This increase in viral load was
associated with a high risk of developing HSILs over a cumulative
2-year period, a seven-fold higher risk estimated by real-time PCR
and a six-fold greater risk by HC2 compared to patients whose
viral loads did not increase during the follow-up period.
We observed a 45%, 2-year cumulative risk of clinically relevant
HSIL for HPV 16, 18, 52, and 58 in women with LSILs and whose
viral loads increased between baseline and 6-month follow-up.
Moreover, women with LSILs who had viral load increase between
baseline and 6 month follow-up for HPV 16, 18, 52, or 58, had risk
of persistent abnormal Pap smear 45-fold greater than did those
who had no increase in viral loads (OR¼45.6, 95% CI¼6.4–326.0,
Po0.001). The frequent monitoring of these women allowed an
early diagnosis of high-risk (HR) HPV, and thereby, early
therapeutic intervention. Indeed HR HPV and especially HPV 16,
18, 52, and 58 infections persisted and progressed throughout the
follow-up period. Van Duin et al (2002) reported similar results
and hypothesised that increasing viral loads over time would
favour viral persistence, and the development of cervical CIN 2/3
or worse.
Women with LSIL cytology who were HPV 16 DNA positive at
baseline did not have significantly increased risk of developing
HSIL (OR¼1.5, 95% CI¼0.4–5.8). One possible explanation
for this is the number of women with LSILs due to HPV 16 was
limited (only 9%), compared to 21% in Castle et al (2005). We
observed that high viral loads (410
5 copies) at baseline reached
marginal significance (P¼0.07) in predicting disease progression
among women with LSILs, consistent with Castle et al (2005).
Additionally, neither repeat abnormal Pap smear nor age older
than 30 years increased the risk of HSIL. Thus, increased HPV 16,
18, 52, and 58 viral loads was the single most important risk factor
for HSIL in our study population.
The increase of viral load detected by both HC2 and real-time
PCR methods predicted disease progression to HSIL, with HPV 16,
18, 52, and 58 viral loads detection correlating well (only 6% of
tested specimens had mixed HPV types) and similar to Pre ´tet et al
(2004). We used a real-time PCR method for E6 HPV 16, 18, 52,
and 58 quantifications to determine whether the HC2 assay could
be suitable as a quantitative viral load assay for clinical practice.
Recent data suggests that HR-HPV load would help to identify
women at high risk for progression to HSIL (Joseffson et al, 2000;
Lorincz et al, 2002). However, due to multiple infections, cross-
reactivity of nononcogenic HPV types, and variability of cellularity
of cervical scrapings, HC2 assay of HR-HPV load has not been
validated as a quantitative test.
Although, specimens with HPV 16, 18, 52, and 58 represent
about 43% of all LSILs (Chen et al, 2006), they represented 73% of
HSILs in our cohort study. As a result of the relatively small
proportion of HPV 16 in women with LSILs in Taiwan, it seems
that distinguishing the risk of cervical precancer among HPV 16-
positive women from the lower risk posed by other oncogenic HPV
types might have limited clinical value. Alternatively, repeat HPV
DNA testing 6 months after baseline testing to determine changes
in viral load (increased or not increased) could predict progression
of disease among women with LSILs due to HPV types 16, 18, 52,
and 58, and might be clinically practical and valuable. Although, it
is useful for ASCUS triage (Solomon et al, 2001), HC2 is not
recommended for LSIL triage because the high proportion of
positive results makes it uninformative (ALTS group, 2000).
Nonetheless, if the elevated risk of HSILs in patients who are
positive for HPV 16, 18, 52, or 58 and have viral load increases over
the first two time points at 6-month interval (33% of patients who
are positive for HPV 16, 18, 52, or 58) warrants more aggressive
treatment, then determination of viral load change (increase) of
individual HPV 16, 18, 52, and 58 types might be useful for the
management of women with LSILs. It is noteworthy that women
who had undetectable HPV or viral loads at 1 log decreased
between baseline and 6 months of follow-up still had 6% (2/34)
risk of developing HSILs (data not shown). These data highlight
that no single test or combination of tests will provide perfect
negative reassurance of cervical precancer or cancer.
Several authors also note that the quantitative measurement of
HPV DNA, as an evolutional predictor or determinant of disease
severity, is of greater value than a single HPV positive result. For
example, the amount of HR HPV DNA increases the grade of the
lesion. This increase was noted for HPV 16, but not for HPV 18, 31,
33, 45, and 56 (Moberg et al, 2004). Moreover, the highest HPV 16
loads are predictive of the appearance of carcinoma in situ before
any intraepithelial lesions are detectable (Joseffson et al, 2000). In
a model of the temporal relationship in HPV-induced carcinoma,
Peitsaro et al (2002) proposed that the probability of HPV DNA
integration increases with high HPV 16 DNA load. In our study,
the median viral loads of HPV type 16 and 52 in women with
cytologies between LSIL and HSIL differed significantly, in
contrast to those of HPV types 18 and 58. In our study, we could
not compare the viral loads between women with integration in
LSILs and women with episomal in LSILs, because of the low
integration rate in LSILs cases. However, we compared the median
viral loads of E6 between women with integration in primary
HSILs and women with episomal in primary HSILs. There were no
significant differences in pooling data (including HPV 16, 18, 52,
or 58) or different type between these two groups of patients (data
not shown).
The value of 1pg of HPV genomeml
 1, which represents the
HC2 assay threshold, corresponds to 10
5 copies of HPV
genomeml
 1. As the cervical samples harboured a mean of
Table 2 OR and 95% confidence intervals (95% CI) for 2-year
cumulative HSIL diagnoses associated with HPV 16, 18, 52, and 58 status,
viral load change, age, high viral load, and repeat Pap smear
Characteristic OR (95% CI) P-value
HPV risk
HPV 16 (n¼14) 1.5 (0.4–5.8) 0.34
HPV 18 (n¼8) 0.6 (0.1–5.3) 0.23
HPV 52 (n¼26) 0.7 (0.2–2.6) 0.34
HPV 58 (n¼13) 0.3 (0.0–2.1) 1.61
Baseline viral load
HPV DNA410
5/or HPV DNApl1 0
5 0.8 (0.2–3.1) 0.07
Viral load change
Viral load increase between baseline and 6-month follow-up for HPV testing
Real-time PCR 8.3 (2.0–34) o0.01
Hybrid capture 2 5.6 (1.5–21.4) o0.01
HPV persistence
Persistent HPV/transient 2.5 (0.5–12.7) 0.27
Age at enrollment
X30 or o30 1.8 (0.3–11.7) 0.19
Repeat Pap smear
Abnormal or normal 2.1 (0.5–8.3) 1.27
P-value o0.05 represents statistical significance (w
2).
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 1, the HC2 cutoff represents 10
5 HPV/5 10
5 cells.
Van Duin et al (2002) proposed that it was 2.4 10
4 HPV 16/
scrape (one scrape contains approximated 0.6 10
5–2.2 10
5
cells) for women with normal cytologies and 4.3 10
6 HPV 16/
scrape for women with abnormal cytologies. The real-time PCR
and HC2 measurements of viral load correlated well, even without
cell normalization in our study (Pearson’s correlation coefficient
r¼0.69, Po0.001). Load changes determined by HC2 also
precisely predicted histological progression of LSILs to HSILs.
In order to elucidate the causal relationship of integration in
LSIL progression to HSILs using real-time PCR method, we
analysed HPV 16, 18, 52, and 58 DNA samples in 178 cervical
swabs from women with LSILs and longitudinally monitored them
every 3 months in a multicentre trial. We detected the integrated
form only in 9/178 (5%) samples with the episomal form.
Additionally, no pure integration was found in women with LSILs
due to HPV 16, 18, 52, and 58 at baseline and during follow-up.
Furthermore, integration (both integrated DNA and episomal
DNA) of HPV 16, 18, 52, or 58 DNA was detected in only 1 of 13
(7.7%) specimens of women during transition from LSILs to
HSILs. Although some studies (Kulmala et al, 2006) reported that
early integration is noted in women with LSILs, our data suggests
that integration is not often detected in women with LSILs, and
probably is not essential for progression during transition from
LSILs to HSILs. On the other hand, the prevalence of integration of
HPV 16, 18, 52, or 58 DNA among women progressing from LSILs
to HSILs is significantly increased (Po0.001), which is comparable
with previous studies showing that integration is often detected in
HSILs (Peitsaro et al, 2002). Although, there was no difference for
HPV 16 infection between women with LSILs and HSILs, this may
be due to small sample size or reasons not yet known. The possible
role of HPV DNA integration may be a late event in carcinogenesis,
especially when it occurs in HSILs or cervical cancer, or when LSIL
skips directly to HSIL after persistent HPV infection.
In conclusion, we recommend that patients with LSIL, HPV
types 16, 18, 52, or 58, consider detecting the viral load with real-
time PCR or HC2 at the first visit and 6 months subsequently.
Those with elevated viral loads are at risk of disease progression
and should be carefully evaluated by colposcopy.
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